Evidence map›Paper›PMID 26745281›Full record

ArticlePloS one2016

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.

Sebastian K Wandinger, Idoya Lahortiga, Kris Jacobs, Martin Klammer, Nicole Jordan, Sarah Elschenbroich, Marc Parade, Edgar Jacoby, Joannes T M Linders, Dirk Brehmer and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Sebastian K WandingerEvotec (München) GmbH, Martinsried, Germany.
Idoya LahortigaVIB Center for the Biology of Disease, Leuven, Belgium.
Kris JacobsVIB Center for the Biology of Disease, Leuven, Belgium.
Martin KlammerEvotec (München) GmbH, Martinsried, Germany.
Nicole JordanEvotec (München) GmbH, Martinsried, Germany.
Sarah ElschenbroichEvotec (München) GmbH, Martinsried, Germany.
Marc ParadeOncology Drug Discovery, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Edgar JacobyOncology Drug Discovery, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Joannes T M LindersOncology Drug Discovery, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Dirk BrehmerOncology Drug Discovery, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Jan CoolsVIB Center for the Biology of Disease, Leuven, Belgium.
Henrik DaubEvotec (München) GmbH, Martinsried, Germany.
Evotec (Germany) · DEJanssen (Belgium) · BEKU Leuven · BEVIB-KU Leuven Center for Cancer Biology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The four members of the epidermal growth factor receptor (EGFR/ERBB) family form homo- and heterodimers which mediate ligand-specific regulation of many key cellular processes in normal and cancer tissues. While signaling through the EGFR has been extensively studied on the molecular level, signal transduction through ERBB3/ERBB4 heterodimers is less well understood. Here, we generated isogenic mouse Ba/F3 cells that express full-length and functional membrane-integrated ERBB3 and ERBB4 or ERBB4 alone, to serve as a defined cellular model for biological and phosphoproteomics analysis of ERBB3/ERBB4 signaling. ERBB3 co-expression significantly enhanced Ba/F3 cell proliferation upon neuregulin-1 (NRG1) treatment. For comprehensive signaling studies we performed quantitative mass spectrometry (MS) experiments to compare the basal ERBB3/ERBB4 cell phosphoproteome to NRG1 treatment of ERBB3/ERBB4 and ERBB4 cells. We employed a workflow comprising differential isotope labeling with mTRAQ reagents followed by chromatographic peptide separation and final phosphopeptide enrichment prior to MS analysis. Overall, we identified 9686 phosphorylation sites which could be confidently localized to specific residues. Statistical analysis of three replicate experiments revealed 492 phosphorylation sites which were significantly changed in NRG1-treated ERBB3/ERBB4 cells. Bioinformatics data analysis recapitulated regulation of mitogen-activated protein kinase and Akt pathways, but also indicated signaling links to cytoskeletal functions and nuclear biology. Comparative assessment of NRG1-stimulated ERBB4 Ba/F3 cells revealed that ERBB3 did not trigger defined signaling pathways but more broadly enhanced phosphoproteome regulation in cells expressing both receptors. In conclusion, our data provide the first global picture of ERBB3/ERBB4 signaling and provide numerous potential starting points for further mechanistic studies.

Indexed as

Signal TransductionAmino Acid SequenceAnimalsB-LymphocytesCell LineGene Expression RegulationGene Regulatory NetworksGenetic EngineeringHumansMiceMolecular Sequence DataNeuregulin-1PhosphoproteinsPhosphorylationProtein BindingProtein Interaction MappingErbB3 protein, mouseErbb4 protein, mouseNeuregulin-1Nrg1 protein, mousePhosphoproteinsProteomeReceptor, ErbB-3Receptor, ErbB-4

Identifiers

PMID26745281
PMCPMC4706443
OpenAlexW2239411523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.